Kingenic launches NSAID range in India

 5 December 2020

Kingenic announces the Indian launch of Kinamol, it is set to enter NSAID market. Nonsteroidal anti-inflammatory drugs (NSAIDs) represent a critically important class of medications useful in numerous musculoskeletal and inflammatory diseases, Kingenic is commited to launch several more product under this class in coming years to make a difference.

Currently Kingenic is set to launch Kinamol under 3 different combination. 

Kinamol Ultra Strength

Salt Composition :

Aceclofenac (100mg) + Paracetamol (325mg) + Serratiopeptidase (15mg)

Kinamol Ultra Strength is a combination medicine used to relieve pain and swelling in various conditions like muscle pain, joint pain and postoperative pain. Thus, it effectively alleviates pain and inflammation in conditions like rheumatoid arthritis, ankylosing spondylitis and osteoarthritis.

Kinamol AD

Salt Composition:

Aceclofenac (100mg) + Drotaverine (80mg)

Kinamol AD is a combination medicine used in the treatment of abdominal pain. It works effectively to reduce abdominal pain, bloating, discomfort and cramps by relaxing the muscles of the stomach and gut. It also blocks certain chemical messengers that cause pain and discomfort.

Kinamol PM

Salt Composition:

Pregabalin (75mg) + Methylcobalamin (1500mcg) 

Kinamol PM is used for the treatment of neuropathic pain. It decreases the pain by modulating calcium channel activity of the nerve cells. This medicine also protects nerve fibers and heal damaged nerve cells.

"We are commited to develop and introduce new drug forms to advance the NSAID segment with easy to administer drugs in coming years and Kingenic is commited to develop nano-formulations of submicron NSAIDs featuring delivery of decreased doses without diminished efficacy." - said, Manan Kinariwala, Founder & CEO - Kingenic Lifescience Pvt. Ltd. (India)



More Stories
Kingenic introduces QR packaging security

Counterfeiting products cause financial losses for legitimate brands, involve social costs and losses of unpaid tax for governments. Kingenic Lifescience has implemented quick response code system on our latest packaging material to enhance traceability.

Kingenic enters GI therapeutics market.

We identify gastrointestinal theapeutic as an important area of treatment. With our entry into GI segment, Kingenic is commited to make maximum impact in coming years.